Patricia Soulard 

Patricia is an experienced molecular pharmacologist with expertise in drug discovery, translational biology and early drug and clinical development in both large pharmaceutical and biotechnology industries.

With over three decades of experience, she has worked on building and advancing innovative and compelling drug target portfolios in oncology, immune-oncology (IO) and inflammation. Before joining Rgenta as Executive Director Translational Biology, Patricia worked on translation & biomarker research at Merck KGaA as Director of Immuno-Oncology Portfolio Strategy and Research Lead for Bavencio. 

Prior to Merck, she was Director of Discovery Biology at Forma Therapeutic exploring emerging biology in oncology and immunology/inflammation for the treatment of diseases with significant unmet medical needs. Before Forma, Patricia founded Duo BioPharma to develop a novel cell-targeted drug modality for treating severe autoimmune diseases. Patricia started her career as an entrepreneurial scientist at Pfizer working for close to two decades including as Head of the Worldwide Drug Pfinder Program.